Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC73627HDAC/JAK/BRD4-IN-1CAS: 2755325-84-7纯度: >95.00%
HDAC/JAK/BRD4-IN-1(化合物25ap)是一种强效的HDAC/JAK/BRD4三重抑制剂。
- GC73634Cu(II)-ElesclomolCAS: 1224195-72-5纯度: >99.00%
Cu(II)-Elesclomol是Elesclomol与 Cu(II)离子形成的1:1螯合物,能诱导铜死亡,具有抗癌活性。
- GC73688Hydroxy-PP-MeCAS: 833481-77-9纯度: >99.00%
Hydroxy-PP-Me是一种强效且特异的CBR1抑制剂,IC50为759nM。droxy PP-Me抑制血清戒断诱导的细胞凋亡。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC73627 | HDAC/JAK/BRD4-IN-1 | 2755325-84-7 | >95.00% | |
HDAC/JAK/BRD4-IN-1(化合物25ap)是一种强效的HDAC/JAK/BRD4三重抑制剂。 | ||||
| GC73629 | FB49 | - | >99.00% | |
FB49是一种高选择性的bcl -2相关的无氧基因3 (BAG3)抑制剂,Ki为45 μM。 | ||||
| GC73630 | ZZM-1220 | - | >98.00% | |
ZZM-1220是一种组蛋白赖氨酸金属转移酶G9a/GLP共价抑制剂,IC50分别为458 nM和924 nM。 | ||||
| GC73631 | FPR1 antagonist 1 | - | >95.00% | |
FPR1 antagonist 1(化合物24a)是甲酰肽受体1(FPR1)拮抗剂,IC50为25nM。 | ||||
| GC73632 | NSC 48160 | 6640-90-0 | >99.00% | |
NSC 48160抑制癌症细胞的生长,CPFAC-1和BxPC-3的IC50分别为84.3μM和94.5μM。 | ||||
| GC73634 | Cu(II)-Elesclomol | 1224195-72-5 | >99.00% | |
Cu(II)-Elesclomol是Elesclomol与 Cu(II)离子形成的1:1螯合物,能诱导铜死亡,具有抗癌活性。 | ||||
| GC73642 | ALK-IN-26 | 2447607-85-2 | >99.00% | |
ALK-IN-26是ALK抑制剂,对ALK酪氨酸激酶的IC50值为7.0 μM。 | ||||
| GC73643 | NBI-961 | 2225902-98-5 | >99.00% | |
NBI-961是一种有效的NEK2抑制剂,可抑制蛋白酶体降解。 | ||||
| GC73678 | RMC-4998 | 2642037-07-6 | >96.00% | |
RMC-4998是一种口服活性抑制剂,靶向KRASG12C突变体的活性或gtp结合状态。 | ||||
| GC73688 | Hydroxy-PP-Me | 833481-77-9 | >99.00% | |
Hydroxy-PP-Me是一种强效且特异的CBR1抑制剂,IC50为759nM。droxy PP-Me抑制血清戒断诱导的细胞凋亡。 | ||||
| GC73697 | STM3006 | 2499664-52-5 | >97.00% | |
STM3006是一种高效、选择性和口服活性的METTL3抑制剂(IC50:5nM)。 | ||||
| GC73719 | BAY 1892005 | 2036352-13-1 | >99.00% | |
BAY 1892005是p53蛋白的调节剂,作用于p53凝聚体而不引起p53突变体的再激活。 | ||||
| GC73725 | RIPK1-IN-17 | - | >98.00% | |
RIPK1-IN-17(化合物10)是RIPK1和RIPK3抑制剂。 | ||||
| GC73740 | DCZ5418 | 2883709-99-5 | >99.00% | |
DCZ5418是TRIP13的抑制剂。 | ||||
| GC73744 | JAB-2485 | 2899209-55-1 | >98.00% | |
JAB-2485是一种有效的选择性极光激酶a (AURKA)抑制剂,IC50为0.33 nM。 | ||||
| GC73760 | Trilexium | 1983180-82-0 | >99.00% | |
Trilexium (TRX-E-009-1)是与TRX-E-002-1结构相关的第三代苯并吡喃。 | ||||
| GC73767 | PKM2-IN-6 | 771467-00-6 | >98.00% | |
PKM2-IN-6(化合物7d)是一种强效的口服活性PKM2抑制剂,IC50值为23nM。 | ||||
| GC73773 | PLK1/BRD4-IN-5 | - | >99.00% | |
PLK1/BRD4-IN-5(化合物SC10)是一种口服活性PLK1和BRD4抑制剂,IC50值分别为0.3 nM和60.8 nM。 | ||||
| GC73774 | YCH2823 | - | >99.00% | |
YCH2823是USP7的抑制剂(IC50 = 49.6 nM;Kd = 0.117 μM)。 | ||||
| GC73795 | T-1-PMPA | 1323883-62-0 | >99.00% | |
T-1-PMPA是一种具有凋亡特性的强效EGFR抑制剂。 | ||||
| GC73808 | Glutor | 2561471-22-3 | >99.00% | |
Glutor是一种选择性GLUT 1/2/3抑制剂,可以抑制葡萄糖摄取。 | ||||
| GC73813 | IOX5 | - | >99.00% | |
IOX5是一种选择性脯氨酸羟化酶(PHD)抑制剂。 | ||||
| GC73822 | GNE-900 | 1200126-26-6 | >99.00% | |
GNE-900是一种ATP竞争性、选择性和口服活性的ChK1抑制剂,ChKl和ChK2的IC50分别为0.0011和1.5µM。 | ||||
| GC73823 | MMs02943764 | 708287-29-0 | >98.00% | |
MMs02943764是一种具有抗癌活性的1,2,4-三唑衍生物。 | ||||
